fda approves osimertinib as adjuvant therapy for non-small cell lung cancer with egfr mutations
Published 3 years ago • 227 plays • Length 3:42Download video MP4
Download video MP3
Similar videos
-
6:01
fda d.i.s.c.o.: osimertinib for non-small cell lung cancer
-
5:03
adaura results: adjuvant osimertinib for egfrm non-small cell lung cancer
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
6:01
fda d.i.s.c.o.: osimertinib for non-small cell lung cancer
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
2:33
adaura: osimertinib adjuvant therapy in egfr mutated nsclc
-
1:21
fda approval of frontline osimertinib in frontline egfr-mutant nsclc
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
3:19
adjuvant osimertinib in resected egfr-mutated nsclc
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
7:28
asco: adjuvant osimertinib for resected egfr-positive non-small cell lung cancer
-
1:42
adaura: the benefit of adjuvant osimertinib
-
0:40
copy of dr. west on fda approval of frontline osimertinib in egfr nsclc
-
3:14
dr. west on fda approval of frontline osimertinib in egfr nsclc
-
3:09
case 2: osimertinib in egfr-mutated lung cancer
-
2:53
oleclumab plus osimertinib for advanced egfrm nsclc
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
6:30
osimertinib adjuvant therapy in patients with early stage egfr mutated nsclc after tumour resection